The Open Targets Blog

MAY 9, 2024

In December 2023, we introduced the pharmacogenetics widget in the Open Targets Platform, which brings in data from PharmGKB on the influence of genetic variation on drug responses. Pharmacogenetics examines the link between genetics and drug response, helping in the prioritisation of drug targets that minimise the risk of adverse effects.

Pharmacogenetics 72

Pharmacogenetics Drugs Therapies Disease 72

Broad Institute

MAY 30, 2024

Introduction to Pharmacogenetics By Rose Circeo May 30, 2024 Breadcrumb Home Introduction to Pharmacogenetics The Primer on Medical and Population Genetics is a series of weekly lectures on genetics topics related to human populations and disease.

Pharmacogenetics 52

Pharmacogenetics Bioethics Disease Research 52

The Open Targets Blog

MARCH 20, 2024

  We have implemented this analysis for eight sources of target-disease association evidence where there is enough information available to make an assessment. The assessment is tailored to each dataset; this is detailed in our target-disease evidence documentation. million evidence. is included as independent evidence.

Pharmacogenetics 85

Pharmacogenetics Disease Drugs Research 85

ASPET

SEPTEMBER 16, 2024

Glioblastoma (GBM) is a disease of the whole brain, with infiltrative tumor cells protected by an intact BBB. GBM has a poor prognosis despite aggressive treatment, in part due to lack of adequate drug permeability at the BBB. Standard of care GBM therapies include radiation and cytotoxic chemotherapy that lead to DNA damage.

Pharmacogenetics 100

Pharmacogenetics DNA Pharmacokinetics Treatment 100

The Open Targets Blog

NOVEMBER 30, 2023

The new page can be accessed from the target-disease associations page when searching for targets associated with a disease, and clicking on the target prioritisation factors tab. Target prioritisation view for Crohn's Disease. Clicking on one of the cells will bring up the data informing the assessment.

Pharmacogenetics 59

Pharmacogenetics Small Molecule Disease Drugs 59

ASPET

AUGUST 4, 2023

These findings have important clinical implications as PMAT could represent a novel molecular marker to help inform disease prognosis and predict response to 131 I-mIBG therapy. PMAT is expressed intracellularly in neuroblastoma cells, transports mIBG and thus could impact tumor retention and response to 131 I-mIBG therapy.

Pharmacogenetics 100

Pharmacogenetics Therapies Disease 100

ASPET

NOVEMBER 17, 2023

Quantitative pharmacokinetic models should therefore focus on OCT2/MATE when describing serum creatinine and creatinine clearance modulation by inhibitor drugs and genotype- or disease-related activity changes.

Pharmacogenetics 100

Pharmacogenetics Pharmacokinetics Disease Drugs 100